Brexogen and BMI Korea Enter Strategic Technology Transfer Agreement for Exosome Therapeutics
Out-licenses BxC-I17e, Exosome-Based Therapeutics for New Indications KRW 3 Billion Non-Refundable Upfront Payment + Milestone Payments + Double-Digit Percentage Royalties SEOUL, South Korea, Feb. 19, 2025 /PRNewswire/ -- Brexogen, a leading...